SCHEMBL4877155

SCHEMBL4877155

CC(C)(C)[Si](C)(C)OCCNc1ccc(-c2csc(C(=O)Nc3ccc(Cl)cn3)c2C(N)=O)cc1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
F10 P00742 15/20 0.40
F2 P00734 16/20 0.39
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
KLKB1 P03952 1/20 0.38
ELANE P08246 1/20 0.38
BRD4 O60885 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
NFKB1 P19838 1/20 0.36
CASP3 P42574 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
SENP6 Q9GZR1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4878300 0.94 F10 (0.38) F10F2NPC1RAB9AKLKB1
SCHEMBL4879114 0.84 F2 (0.38) F10F2NPC1RAB9AKLKB1
Formamide SCHEMBL4878302 0.80 PTPN1 (0.32) SMN1; SMN2
SCHEMBL4882648 0.79 F10 (0.43) F10F2NPC1RAB9AKLKB1
SCHEMBL14066578 0.79 F10 (0.43) F10F2NPC1RAB9AKLKB1
SCHEMBL4876089 0.78 F10 (0.37) F10F2NPC1RAB9AKLKB1
SCHEMBL4710501 0.77 RAB9A (0.42) NPC1RAB9ABRD4ALDH1A1LMNA
SCHEMBL14066579 0.76 GRM5 (0.40) F10NPC1RAB9AALDH1A1LMNA
SCHEMBL4873941 0.76 GRM5 (0.40) F10NPC1RAB9AALDH1A1LMNA
SCHEMBL4881623 0.75 SMN1; SMN2 (0.38) F10NPC1RAB9ABRD4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080214533-A1 Cyclic Iminocarbamates And Their Use BAYER HEALTHCARE AG (DE) 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214533-A1 Cyclic Iminocarbamates And Their Use F2, UQCRB, F12 F10 26/4885F2 1/4885NPC1 1777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.